Seria Co., Ltd. (TYO:2782)

Inozyme Pharma Revenue

Seria had revenue of 60.50B JPY in the quarter ending June 30, 2025, with 4.70% growth. This brings the company's revenue in the last twelve months to 238.71B, up 4.94% year-over-year. In the fiscal year ending March 31, 2025, Seria had annual revenue of 236.33B with 5.88% growth.

• Revenue (ttm): 238.71B
• Revenue Growth: +4.94%
• P/S Ratio: 0.98
• Revenue / Employee: 422.50M
• Employees: 565
• Market Cap: 233.24B

Revenue History

Fiscal Year End	Revenue	Change	Growth
Mar 31, 2025	236.33B	13.13B	5.88%
Mar 31, 2024	223.20B	10.84B	5.11%
Mar 31, 2023	212.36B	4.28B	2.05%
Mar 31, 2022	208.08B	7.40B	3.69%
Mar 31, 2021	200.68B	19.21B	10.58%